<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193959</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-02/2010</org_study_id>
    <nct_id>NCT01193959</nct_id>
  </id_info>
  <brief_title>Pemetrexed in Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Present study is aimed at investigating potential molecular predictors of sensitivity or
      resistance to single-agent pemetrexed in the â‰¥ second line setting in a large cohort of
      advanced non-small cell lung cancer (NSCLC) patients. The following biomarkers will be
      investigated with either immunohistochemistry, fluorescence in situ hybridization or
      genotyping: thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide
      ribonucleotide formyl transferase (GARFT), aminoimidazole carboxamide ribonucleotide
      formyltransferase (ATIC/AICARFT), epidermal growth factor receptor (EGFR), Kirsten rat
      sarcoma 2 viral oncogene homolog (KRAS), v-myc myelocytomatosis viral oncogene homolog (MYC)
      and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of each biomarker with treatment outcome in terms of response rate, time to progression, overall survival.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of each biomarker with clinico-pathological features: histology, gender, age, smoking status, response to previous chemotherapy.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non-small cell lung cancer patients treated with single agent pemetrexed
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor
             tissue available at our institution

          -  Patients treated with single agent pemetrexed for metastatic disease

          -  Availability of full clinical data

        Exclusion Criteria:

          -  Cytological diagnosis of advanced Non-small cell lung cancer

          -  Lack of tumor tissue at our institution

          -  Lack of full clinical data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando SANTORO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Armando Santoro, MD</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

